Crinetics Pharmaceuticals, Inc.
CRNX
$34.47
-$0.57-1.63%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -4.90% | -3.74% | -10.65% | -11.37% | -4.59% |
| Total Depreciation and Amortization | 2.34% | 2.26% | 58.86% | 80.92% | -4.03% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.35% | -5.50% | 49.27% | -16.21% | 18.44% |
| Change in Net Operating Assets | 85.69% | -118.87% | 323.59% | -67.57% | 71.01% |
| Cash from Operations | -2.95% | -37.72% | 13.70% | -37.23% | 6.83% |
| Capital Expenditure | -94.89% | 44.71% | 28.30% | -42.46% | 73.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2,660.50% | 140.11% | -3,310.60% | 101.90% | 54.49% |
| Cash from Investing | -2,731.11% | 138.41% | -17,459.55% | 100.35% | 54.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 896.38% | 973.17% | -98.66% | 953.48% | -89.19% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2,037.10% | -10,842.86% | 100.09% | -1,590.91% | 95.64% |
| Cash from Financing | 866.45% | 943.07% | -98.60% | 937.77% | -88.78% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -449.00% | 116.11% | -127.49% | 487.98% | -185.14% |
